Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety Follow-up Through 180 Days of Treatment With Remestemcel-L in Study MSB-GVHD001 in Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD

NCT02652130 is registered in ClinicalTrials.gov with Mesoblast, Inc. as lead sponsor.

NCT NCT02652130
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02652130 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety Follow-up Through 180 Days of Treatment With Remestemcel-L in Study MSB-GVHD001 in Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Lead sponsor
Mesoblast, Inc.
Phase
Phase 3
Overall status
Completed
Start date
October 28, 2015
Completion date
June 15, 2018
Enrollment
32 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

grade b acute graft versus host disease, grade c acute graft versus host disease, grade d acute graft versus host disease